How Much Alcohol Can I Drink on Methotrexate?

Moderate alcohol intake, roughly up to 14 standard units per week, does not appear to raise the risk of liver damage in people taking methotrexate for conditions like rheumatoid arthritis or psoriasis. That finding, from the largest study directly measuring alcohol’s effect on methotrexate-related liver injury, is considerably more permissive than the blanket “avoid all alcohol” warning many patients receive. The real picture depends on how much you drink, what condition you’re being treated for, and whether you have other risk factors that stress the liver independently.

What the Largest Study Found

The most cited research on this question followed over 11,000 rheumatoid arthritis patients on methotrexate, tracking their alcohol intake against liver enzyme elevations (a sign the liver is under stress). Drinking up to 7 units per week showed no increased risk compared to not drinking at all. Drinking 8 to 14 units per week also showed no meaningful increase. It was only above 21 units per week that the risk climbed to a statistically clear level, with roughly an 85 percent higher rate of abnormal liver enzymes compared to non-drinkers. The range between 15 and 21 units fell in a gray zone: possibly elevated risk, but not enough to be certain from the data.¹

An older meta-analysis of liver biopsies in methotrexate patients drew a similar line, though from a different angle. Patients classified as heavy drinkers, consuming at least 100 grams of alcohol per week (roughly 12 to 13 standard drinks), were about four times more likely to show advanced liver changes on biopsy than lighter or non-drinkers, and far more likely to show worsening over time.² Together, these studies suggest the threshold for real trouble sits well above a glass of wine with dinner a few times a week.

How to Count a “Unit”

The 14-unit threshold comes from UK research, and a UK unit equals 10 milliliters (8 grams) of pure alcohol. That’s smaller than a U.S. “standard drink,” which contains about 14 grams. In practical terms, 14 UK units works out to roughly 7 U.S. standard drinks per week, or one drink per day. A single 5-ounce glass of wine, a 12-ounce regular-strength beer, or a 1.5-ounce shot of spirits each count as one U.S. standard drink. If your prescriber tells you “a few drinks a week is fine,” that aligns reasonably well with what the evidence supports, but it helps to know the actual math so you’re not inadvertently doubling the count with heavy pours or high-ABV craft beers.

Why the Liver Takes the Hit From Both Sides

Methotrexate and alcohol each stress the liver through overlapping pathways, which is why combining them raises concern. Methotrexate is converted inside cells into a metabolite that triggers oxidative stress, promotes inflammation, and can lead to fat buildup and scarring in liver tissue over time.³ Alcohol undergoes its own metabolism that generates reactive molecules and triggers many of the same inflammatory signals in the liver.⁴ When both are present, the liver faces a compounded version of a challenge it’s already managing from one direction. At low doses, though, the liver’s repair capacity appears to handle the combined load without measurable damage, which is why moderate drinking doesn’t move the needle in the studies.

Low-Dose Methotrexate Is Not High-Dose Methotrexate

One reason patients get overly alarmed is that methotrexate carries a fearsome reputation from oncology, where it’s given at doses many times higher than for autoimmune diseases. The weekly 7.5 to 25 mg dose used for rheumatoid arthritis, psoriasis, or Crohn’s disease works through different mechanisms and carries a substantially different side-effect profile than the doses used to treat cancer.⁵ When your rheumatologist or dermatologist says “methotrexate is generally well tolerated,” they’re speaking from evidence specific to low-dose use. The horror stories that circulate online often conflate the two, which skews the perceived risk of moderate drinking unfairly high.

Other Risk Factors That Matter More

Here’s where the evidence gets genuinely surprising. Several large studies have found that the total dose and duration of methotrexate treatment are not the strongest predictors of liver fibrosis. Instead, metabolic conditions like obesity and diabetes dominate. A study measuring liver stiffness (a proxy for fibrosis) in long-term methotrexate users found that diabetes was the strongest independent predictor, while neither cumulative methotrexate dose nor treatment duration showed a significant association.⁶ A separate study of over 500 patients on methotrexate for various inflammatory diseases found similar results: body mass index over 28 and high alcohol consumption predicted abnormal fibrosis markers, but methotrexate dose and duration did not.⁷

This reframes the question in an important way. If you’re on methotrexate and wondering about alcohol, the honest answer is that your weight and metabolic health probably matter more to your liver’s long-term safety than whether you have a beer on Saturday. That doesn’t make alcohol irrelevant, but it does mean the conversation with your doctor should include the full picture: your BMI, whether you have fatty liver disease, whether your blood sugar is well controlled, and what other medications you take. Factors like genetic variations in folate metabolism and concurrent use of other liver-stressing drugs also play a role.⁸

How Folic Acid Helps

Most prescribers now routinely add folic acid supplementation alongside methotrexate, and the evidence for doing so is strong. A Cochrane review found that folic acid or folinic acid reduced the risk of abnormal liver enzyme elevation by about 77 percent in methotrexate-treated rheumatoid arthritis patients.⁹ If you’re drinking within moderate limits and taking your folic acid as prescribed, you’ve already stacked the odds in the liver’s favor. If your prescriber hasn’t discussed folic acid supplementation, it’s worth asking about. The protective effect against liver toxicity is one of the most clear-cut findings in this entire area.

Your Underlying Condition Changes the Equation

Not everyone on methotrexate faces the same liver risk, and the disease being treated turns out to matter independently. A population-based study comparing over 40,000 patients found that people with psoriasis on methotrexate were 1.6 to 3.4 times more likely to develop liver disease outcomes compared to rheumatoid arthritis patients, even after adjusting for alcohol use, comorbidities, and methotrexate dose. Those with psoriatic arthritis fell in between, at roughly 1.3 to 1.6 times the risk for milder liver disease and cirrhosis.¹⁰ A smaller comparison found that psoriatic arthritis patients had nearly double the rate of liver enzyme elevations compared to rheumatoid arthritis patients.¹¹

Why the difference? Psoriasis and psoriatic arthritis are closely linked with metabolic syndrome, obesity, and fatty liver disease at higher rates than rheumatoid arthritis. The inflammatory disease itself creates a liver-hostile environment before methotrexate or alcohol enters the picture. If you have psoriasis and are already carrying extra weight or have been told you have fatty liver, the safe margin for alcohol may genuinely be narrower for you than the 14-unit-per-week threshold measured in a predominantly rheumatoid arthritis population. That study’s numbers can’t simply be transplanted to every methotrexate patient without considering the underlying condition.

How Liver Monitoring Works on Methotrexate

Routine blood tests are the first line of defense. Most prescribers check liver enzymes (ALT and AST) every one to three months while you’re on methotrexate. A single elevated reading doesn’t necessarily mean damage; it could reflect a recent illness, a dose change, or other medications. Persistent elevations, especially two to three times the upper limit of normal across multiple tests, typically prompt your doctor to pause methotrexate or investigate further.

Standard blood work has a well-known limitation, though: liver enzymes can stay normal even when significant fibrosis is developing underneath. One study of psoriasis patients on long-term methotrexate found that standard and dynamic liver function tests were often in the normal range in patients who actually had fibrosis or cirrhosis on biopsy.¹² This is part of why liver biopsy used to be the gold standard for monitoring long-term methotrexate users, and why many older guidelines recommended routine biopsies after certain cumulative doses.

In recent years, a non-invasive alternative called transient elastography (commonly known by the brand name FibroScan) has largely replaced biopsy for routine monitoring. It uses ultrasound to measure liver stiffness, which correlates well with fibrosis. Meta-analyses across chronic liver diseases report high accuracy for detecting cirrhosis, and recent guidelines recommend it as the first-line fibrosis assessment in liver conditions including fatty liver disease.¹³ Some guidelines now suggest repeating elastography every three years for patients with normal readings and yearly for those with borderline results. If you’ve been on methotrexate for years and haven’t had an elastography scan, asking about one can give you more reassurance than blood tests alone, especially if you drink socially.

How Guidelines Have Shifted

Medical guidelines on alcohol and methotrexate used to be much stricter. Older guidance, particularly from rheumatology bodies in the UK, essentially told patients to avoid alcohol entirely. That advice softened as better evidence accumulated. A review examining the basis for updated British Society for Rheumatology guidelines found no evidence contradicting the relaxation of alcohol advice for methotrexate patients.¹⁴ Current guidance from major rheumatology organizations in both the UK and the US generally permits light-to-moderate drinking while emphasizing that heavy or binge drinking should be avoided.

That said, “guidelines permit it” and “your individual doctor permits it” are two different things. Some clinicians remain conservative, particularly if you’re newly starting methotrexate, have existing liver concerns, or have a history of heavy drinking. If your prescriber advises strict abstinence, it’s worth asking what specific risk factors are driving that recommendation rather than assuming it’s the default for everyone.

Binge Drinking vs. Spread-Out Drinking

The research on methotrexate and alcohol generally measures total weekly intake, not the pattern of consumption. But liver science more broadly suggests that how you distribute your drinks matters. Consuming seven drinks on a Saturday night delivers a concentrated toxic load to the liver in a short window, producing much higher peak levels of the harmful metabolites than the same seven drinks would generate if spread across a week. The methotrexate-specific studies don’t directly test this, so the evidence here is borrowed from general hepatology rather than specific to this drug. Still, common sense and the basic biology of liver metabolism both point the same direction: spreading your intake across multiple days is gentler on the liver than concentrating it.

Methotrexate is typically taken once a week, and some patients ask whether to avoid drinking on the same day they take their dose. There’s no clinical trial answering that exact question, but the reasoning is straightforward. Methotrexate blood levels are highest in the hours following your dose, and adding alcohol to the liver’s workload during that peak doesn’t make pharmacological sense if you can easily avoid it. Many rheumatologists suggest skipping alcohol on methotrexate day and perhaps the following day, then drinking moderately on the remaining days if you choose.

When Abstinence Really Is the Safer Call

The permissive data has limits, and certain situations warrant more caution or complete avoidance of alcohol:

Pre-existing liver disease: If you already have hepatitis, fatty liver disease, or elevated baseline enzymes, you’re starting from a compromised position. The study finding that moderate drinking is safe was measured in a general population that included but wasn’t dominated by people with existing liver problems.
Diabetes or obesity: Both are stronger predictors of fibrosis in methotrexate patients than the drug itself. Adding any alcohol to that metabolic load may push risk in a way that standard studies wouldn’t capture, since those studies adjust for these variables rather than focusing on the combined effect.
History of heavy drinking: A liver that has already endured years of heavy alcohol exposure may not have the same regenerative margin as one that hasn’t. The “moderate drinking is fine” data doesn’t specifically account for prior cumulative damage.
Multiple hepatotoxic medications: If you’re also taking drugs like leflunomide, certain antibiotics, or high-dose acetaminophen (paracetamol), the combined burden on the liver adds up in ways that haven’t been individually studied with alcohol on top.
Persistently elevated liver enzymes: If your routine blood work is already showing stress signals from methotrexate alone, alcohol is adding fuel to an active problem.

The Fibrosis Risk May Be Lower Than You’ve Heard

For years, methotrexate carried a reputation as a drug that inevitably scars the liver if taken long enough. More recent evidence has pushed back hard on that narrative. A 2023 study specifically titled its conclusion to make the point: the risk of liver fibrosis from long-term methotrexate may be overestimated. The investigators found that metabolic factors, not methotrexate itself, drove fibrosis in their cohort.⁶ Similarly, the large case-control study of 518 patients found severe fibrosis markers in only about 8.5 percent of methotrexate users, and the strongest predictors were high BMI and heavy alcohol, not the drug’s dose or how long people had taken it.⁷

This doesn’t mean methotrexate is benign to the liver. It does mean that if you’re a healthy-weight person with no diabetes, taking your folic acid, getting your liver enzymes checked on schedule, and drinking within moderate limits, the liver risk from methotrexate is lower than the warnings on the prescription leaflet might lead you to believe. The patients who run into serious trouble are overwhelmingly those with several compounding risk factors, and heavy drinking is one of those factors, not the only one.